York, UK and Madison, WI, USA, 16 November 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces it has signed a Memorandum of Understanding (‘MoU’) with Centre for Process Innovation (‘CPI’) to explore opportunities for collaboration across the MedTech sector.
The relationship will create a clear route for diagnostics innovators to progress from early-stage technology development through product validation, regulatory approval, scale-up manufacturing and commercial deployment.
The agreement brings together CPI’s expertise in developing complex MedTech technologies, including diagnostics, biosensors, connected health devices and advanced medical products, with Abingdon Health’s established contract development and manufacturing capabilities, performance evaluation, regulatory expertise, clinical trial management and commercialisation support.
Following Abingdon’s recent expansion into the US, the MoU will further the organisation’s ability to respond to growing demand for innovative development and manufacture of rapidly deployable diagnostic testing solutions in the market.
By aligning their complementary capabilities, the organisations aim to support MedTech companies in overcoming one of the sector’s most significant challenges: bridging the gap between breakthrough innovation and successful commercial adoption.
Under the MoU, CPI and Abingdon Health will work together to identify opportunities where CPI can support innovators during the early phases of technology development, proof of concept, prototyping and process development. Programmes can then be transitioned to Abingdon Health for product verification, validation, regulatory support and scalable manufacturing. Both organisations hold ISO 13485-certified quality systems which will further simplify and accelerate any transfer.
Supporting innovation from concept to commercial impact
The organisations expect the collaboration to create opportunities across a broad range of MedTech applications, including in vitro diagnostics, biosensors, wearable technologies, digital health solutions and next-generation medical devices. By combining CPI’s product development and manufacturing innovation expertise with Abingdon Health’s commercialisation capabilities, the partnership will help innovators reduce risk, shorten development timelines and improve their path to market readiness.
Anthony Celli, Commercial Director of CPI, said:
“The UK and US are home to world-class MedTech innovation, but many developers face challenges when moving from technology development to commercial manufacturing and regulatory approval. By combining CPI’s expertise in technology development and scale-up with Abingdon Health’s proven capabilities in manufacturing, validation and regulatory support, we can provide innovators with a clearer pathway to market and help accelerate the delivery of transformative healthcare technologies.”
Chris Hand, Executive Chairman of Abingdon Health, commented:
“Abingdon Health has built an integrated offering that helps MedTech and diagnostic innovators navigate the critical stages between development and commercialisation. Through this partnership with CPI, we can engage with promising technologies earlier in their journey and provide a seamless route to product verification, regulatory approval and scalable manufacture. Together, we are creating a compelling proposition for companies looking to bring innovative healthcare solutions to market.”
Enquiries:
| Abingdon Health plc | www.abingdonhealth.com/investors/ | |
| Chris Hand, Executive Chairman | Via Walbrook PR | |
| Tom Hayes, CFO | ||
| Cavendish Capital Markets Ltd (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7220 0500 | |
| Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)
Nigel Birks (Life Science Specialist Sales) |
||
| Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base. The Group’s CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.
Abingdon’s regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company’s subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.
Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health’s brochures outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.
About Centre for Process Innovation (‘CPI’)
Making innovation manufacturable: we help innovators validate, scale and manufacture faster, safer and with less risk.
CPI connects the dots within the innovation ecosystem to make great ideas and inventions a reality to benefit people, places and our planet. We’re a pioneering social enterprise that accelerates the development, scale-up and commercialisation of deep tech and sustainable manufacturing solutions. Through our incredible innovation experts and infrastructure, we look beyond the obvious to transform healthcare and drive towards a sustainable future.
As a trusted partner of industry, founders, academia, government, and the investment community, we’re the catalyst for delivering smart AgriFoodTech, energy storage, HealthTech, materials, and pharma innovations. We believe by working together we can build a better collective future, and as part of the High Value Manufacturing Catapult, we facilitate access to world-class organisations to deliver transformation across industries.
Creating lasting global impact from the North of England and Scotland, we invest in people and disruptive technologies to invigorate economies, create circular supply chains and make our world a better place.